Literature DB >> 22378251

Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock.

Milena Soriano Marcolino1, Cihan Simsek, Sanneke P M de Boer, Ron T van Domburg, Robert-Jan van Geuns, Peter de Jaegere, K Martijn Akkerhuis, Joost Daemen, Patrick W Serruys, Eric Boersma.   

Abstract

OBJECTIVES: To determine the risk of short- and long-term mortality and major adverse cardiac events (MACE) in acute myocardial infarction (AMI) patients complicated by cardiogenic shock (CS) in the contemporary practice of primary percutaneous coronary intervention with stenting.
METHODS: Of the 1,755 consecutive AMI patients undergoing percutaneous coronary intervention with stenting enrolled, 103 had CS at admission. Primary endpoints were early mortality (within 30 days after the index event) and late mortality (from day 31 up to 4 years). Secondary endpoints included MACE [all-cause death, myocardial infarction or target vessel revascularization (TVR)], myocardial infarction, TVR and stent thrombosis.
RESULTS: Thirty-day mortality was higher among CS patients, and CS was a strong independent predictor of a higher risk of early death (adjusted HR 3.64, 95% CI 2.44-5.44). The late mortality rate was significantly higher in CS patients, and CS was also a predictor of higher risk of death at a 4-year follow-up (adjusted HR 1.95, 95% CI 1.11-3.45). Recurrent AMI, TVR and stent thrombosis rates were similar among patients with and without CS.
CONCLUSION: CS complicating AMI is still a severe clinical event, mainly with regard to a significant higher risk of early mortality, but also associated with a worse prognosis in 30-day survivors.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378251     DOI: 10.1159/000336154

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  6 in total

Review 1.  Therapeutic Advances in the Management of Cardiogenic Shock.

Authors:  Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Peter S Pang; Razvan I Radu; Elena-Laura Antohi; Josep Masip; Javed Butler; Vlad Anton Iliescu
Journal:  Am J Ther       Date:  2019 Mar/Apr       Impact factor: 2.688

2.  Diagnostic efficacy of serum ST2 in patients with ASC.

Authors:  Yaping Ren; Min Hou; Yunxia Ren; Lei Zhang
Journal:  J Clin Lab Anal       Date:  2022-05-25       Impact factor: 3.124

3.  Cardiogenic Shock with Complete Atrio-ventricular Block in an Octogenarian Woman: Are we going too far?

Authors:  Ziad Dahdouh; Adrien Lemaitre; Vincent Roule; Vincent Troussard; Gilles Grollier
Journal:  Oman Med J       Date:  2014-07

4.  Gender differences in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial.

Authors:  Karl Fengler; Georg Fuernau; Steffen Desch; Ingo Eitel; Franz-Josef Neumann; Hans-Georg Olbrich; Antoinette de Waha; Suzanne de Waha; Gert Richardt; Marcus Hennersdorf; Klaus Empen; Rainer Hambrecht; Jörg Fuhrmann; Michael Böhm; Janine Poess; Ruth Strasser; Steffen Schneider; Gerhard Schuler; Karl Werdan; Uwe Zeymer; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2014-10-07       Impact factor: 5.460

5.  Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention.

Authors:  Yan-Peng Wang; Jian-Hua Wang; Xiao-Long Wang; Jun-Yi Liu; Fang-Yun Jiang; Xiao-Li Huang; Jing-Yu Hang; Wei Qin; Shi-Xin Ma; Jie Zhang; Min-Jie Yuan; Jing-Bo Li; Zhi-Gang Lu; Meng Wei
Journal:  J Cell Mol Med       Date:  2017-06-17       Impact factor: 5.310

6.  Prognostic Value of Circulating MG53 Levels in Acute Myocardial Infarction.

Authors:  Hongyang Xie; Zijun Yan; Shuo Feng; Tianqi Zhu; Zhengbin Zhu; Jingwei Ni; Jun Ni; Run Du; Jinzhou Zhu; Fenghua Ding; Shengjun Liu; Hui Han; Hang Zhang; Jiaxin Zhao; Ruiyan Zhang; Weiwei Quan; Xiaoxiang Yan
Journal:  Front Cardiovasc Med       Date:  2020-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.